北美单克隆抗体市场预测至 2028 年 - COVID-19 影响和区域分析（按来源（人、人源化、嵌合和鼠）、生产方法（体外和体内）、适应症（癌症、自身免疫性疾病、传染病）疾病、炎症性疾病、微生物疾病等）、应用（治疗应用、诊断应用和研究应用）、最终用户（医院、研究所等）
No. of Pages: 169 | Report Code: TIPRE00027987 | Category: Life Sciences
No. of Pages: 169 | Report Code: TIPRE00027987 | Category: Life Sciences
北美区域市场的有利政府法规在大流行爆发期间授权使用单克隆抗体。例如，2021 年 12 月，美国食品和药物管理局 (FDA) 宣布对阿斯利康的 Evusheld（tixagevimab 与 cilgavimab 共同包装并一起给药）获得紧急使用授权 (EUA)，用于 COVID-19 的暴露前预防对于某些成人和儿童。由于单克隆抗体是实验室制造的蛋白质，涉及模仿免疫系统抵抗病毒等有害病原体的能力。因此，“Tixagevimab”和“cilgavimab”是专门针对 SARS-CoV-2 刺突蛋白的长效单克隆抗体。除此之外，在北美地区市场大流行期间，生物制剂开发的有利资金进一步促进了单克隆抗体的市场增长。例如，美国国际开发金融公司（DFC）宣布向 Biological E Limited 提供 5000 万美元，用于提高 COVID-19 疫苗生产能力。此外，FDA 与生物制剂产品批准相关的优惠政策也对市场增长产生了积极影响。
凭借新功能和技术，供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动单克隆抗体市场。北美单克隆抗体市场预计在预测期内将以良好的复合年增长率增长。
Strategic insights for North America Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 54,629.4 Million |
| Market Size by 2028 | US$ 1,20,713.2 Million |
| Global CAGR (2021 - 2028) | 12.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 来源
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Monoclonal Antibodies Market is valued at US$ 54,629.4 Million in 2021, it is projected to reach US$ 1,20,713.2 Million by 2028.
As per our report North America Monoclonal Antibodies Market, the market size is valued at US$ 54,629.4 Million in 2021, projecting it to reach US$ 1,20,713.2 Million by 2028. This translates to a CAGR of approximately 12.0% during the forecast period.
The North America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Monoclonal Antibodies Market report:
The North America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Monoclonal Antibodies Market
